Inotiv, Inc. (NOTVQ) Stock Price & Analysis
Inotiv, Inc. (NOTVQ) fell 44.50% to USD 0.01 as of July 25, 2026 at 05:22 UTC, according to Nexqual real-time market data.
NOTVQ last closed at USD 0.02; the session ranged USD 0.01–0.02 on volume of 82,393 shares. Market capitalization is $390,419, with a 52-week range of USD 0.01–2.43 (PNK). Source: Nexqual, July 25, 2026 at 05:22 UTC.
Key Statistics (as of July 25, 2026 at 05:22 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▼ 44.50% (down) |
| Previous Close | USD 0.02 |
| Open | USD 0.01 |
| Day Range | USD 0.01 – 0.02 |
| 52-Week Range | USD 0.01 – 2.43 |
| Volume | 82,393 shares |
| Market Cap | $390,419 |
| Exchange | PNK |
Technical Analysis (NOTVQ)
Nexqual's technical model rates NOTVQ "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of July 25, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.92 (neutral) |
| vs SMA50 | Below (USD 0.11) |
| MACD | -0.02 (negative) |
Analyst Ratings (NOTVQ)
Wall Street analysts rate NOTVQ "None", per Nexqual as of July 25, 2026 at 05:22 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (NOTVQ)
| Next Earnings Date | 2026-08-05 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.94 vs est -0.64 ▼ miss |
| 2025-12-31 | USD -0.83 vs est -0.64 ▼ miss |
| 2025-09-30 | USD -0.21 vs est -0.08 ▼ miss |
| 2025-06-30 | USD -0.48 vs est -0.15 ▼ miss |
Source: Nexqual, July 25, 2026 at 05:22 UTC.
Financials & Fundamentals (NOTVQ)
| Total Revenue | $507.36M |
|---|---|
| Revenue Growth (YoY) | -5.40% |
| Gross Margin | +22.94% |
| Operating Margin | -16.03% |
| Profit Margin | -17.14% |
| ROE | -74.09% |
| Debt / Equity | 632.65 |
| Current Ratio | 0.27 |
| Total Cash | $15.18M |
| Total Debt | $487.77M |
| Free Cash Flow | $23.62M |
Source: Nexqual, July 25, 2026 at 05:22 UTC.
Financial Health Score (NOTVQ)
Nexqual rates Inotiv, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 05:22 UTC.
| Growth | Mixed — Revenue +4.5% YoY (annual), slow |
|---|---|
| Profitability | Weak — Gross margin 23%, operating -16% |
| Balance Sheet | Critical — $15M cash vs $488M debt |
| Cash Flow | Mixed — FCF $24M, slim 4.6% margin |
| Efficiency | Critical — ROE -74%, ROA -4.0% |
Ownership (NOTVQ)
| Insider Ownership | +8.56% |
|---|---|
| Institutional Ownership | +13.61% |
| Shares Outstanding | 35.17M |
| Float | 32.62M |
| Short % of Float | +7.86% |
Source: Nexqual, July 25, 2026 at 05:22 UTC.
Leadership (NOTVQ)
Inotiv, Inc. is led by Robert W. Leasure (age 65), President, CEO & Director, per Nexqual as of July 25, 2026 at 05:22 UTC.
| President, CEO & Director | Robert W. Leasure (age 65) |
|---|---|
| EVP & CFO | Beth A. Taylor (age 60) |
| Chief Strategy Officer & Director | John E. Sagartz D.V.M., DiplomateACVP (age 59) |
| Chief Operating Officer of DSA | John Gregory Beattie DSA (age 58) |
| Group President of RMS | Lizanne Muller |
Major Backers & Investors (NOTVQ)
Notable institutional backers of Inotiv, Inc. include UBS Group AG, Fidelity, Massar Capital Management, LP , according to Nexqual as of July 25, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| UBS Group AG | 1.84% |
| Fidelity | 1.15% |
| Massar Capital Management, LP | 0.98% |
| Vantage Point Financial LLC | 0.96% |
| Renaissance Technologies | 0.62% |
| Jane Street Group, LLC | 0.45% |
| Fifth Third Bancorp | 0.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.86% |
| Geode Capital | 1.34% |
| BlackRock | 1.19% |
Source: Nexqual, July 25, 2026 at 05:22 UTC.
From Inotiv, Inc.'s Latest SEC 10-K Filing (filed 2025-12-05)
Key Strengths & Strategy (as disclosed to the SEC)
- After successful completion of Phase III trials, the sponsor of the new drug submits a New Drug Application ("NDA") or Biologics License Application ("BLA") to the FDA requesting that the product be approved for marketing.
- Nonclinical Services Our animal research facilities are subject to a variety of federal and state laws and regulations, including rules and regulations enforced by the National Institutes of Health ("NIH") and the United States Department of Agriculture ("USDA"), such as the Animal Welfare Act ("AWA").
- All employees enter into confidentiality agreements intended to protect our proprietary information.
- Application of this technology allows us to rapidly develop and validate methods for new compounds and obtain information suitable for regulatory submission.
Partnerships
- In addition, prior to Inotiv's acquisition of Envigo, Envigo entered into a five-year supplier agreement with a key strategic partner that included minimum purchase commitments through the end of the third year of the agreement and preferred pricing (equal to best price extended to similar clients).
- We believe further that the reliance of the pharmaceutical industry on small innovative drug discovery companies, which are often overlooked by large CROs, creates an opportunity for strategic partnership with mid-market, consulting-based and innovative CROs such as ours.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ICCC | ImmuCell Corporation | USD 11.03 | ▼ 0.9% |
| CSBR | Champions Oncology, Inc. | USD 6.13 | ▲ 0% |
| BNTC | Benitec Biopharma Inc. | USD 11.47 | ▲ 0.26% |
| CBIO | Crescent Biopharma, Inc. | USD 16.3 | ▲ 2.97% |
| STIM | Neuronetics, Inc. | USD 1.73 | ▼ 10.36% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:22 UTC. This page is informational and not investment advice.